T2 Biosystems Announces 2017 Third Quarter Financial and Operational Results Release and Conference Call Date
16 October 2017 - 11:00PM
T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the
development of innovative diagnostic products to improve patient
health, today announced that it will release its 2017 third quarter
financial and operational results after the market closes on
Thursday, November 2, 2017. In conjunction with the release, the
Company will host a conference call with the investment community
at 4:30 p.m. Eastern Time on Thursday, November 2, 2017, to discuss
the financial results and other business developments.
Interested parties may access the live call via
telephone by dialing 1-877-407-9208 (U.S.) or 1-201-493-6784
(International). To listen to the live call via T2 Biosystems'
website, go to www.t2biosystems.com, in the
Investors/Events & Presentations section. A webcast replay of
the call will be available following the conclusion of the call,
also in the Investors/Events & Presentations section of the
website.
About T2 Biosystems:
T2 Biosystems, an emerging leader in the field
of in vitro diagnostics, is dedicated to saving lives and reducing
the cost of healthcare by empowering clinicians to effectively
treat patients faster than ever before. T2 Biosystems is focused on
addressing critical unmet needs in healthcare starting with sepsis,
one of the deadliest and most expensive conditions in hospitals
today. The T2Sepsis SolutionTM is a unique approach that combines
the standard of care for the management of sepsis patients with T2
Biosystems’ products, including the T2Dx® Instrument and T2Candida®
Panel, and the T2Bacteria® Panel, which is commercially available
in Europe and other countries that accept the CE Mark and available
for research use only in the U.S. Powered by the proprietary T2
Magnetic Resonance technology, or T2MR®, the T2Sepsis Solution is
proven to deliver better patient care and greater cost savings.
Hospital customer experience has demonstrated faster time to
effective treatment, shortened ICU and hospital lengths of stay,
reduced use of unnecessary antifungals, and millions of dollars in
savings. T2 Biosystems has an active pipeline of future sepsis
products including additional species and antibiotic resistance, as
well as tests for Lyme disease and hemostasis. For more
information, please visit www.t2biosystems.com.
Company Contact:
Darlene Deptula-Hicks, T2 BiosystemsSVP & Chief Financial
Officerddeptula@t2biosystems.com 603-553-5803
Media Contact:Amy Phillips, Feinstein Kean
Healthcare amy.phillips@fkhealth.com 412-327-9499
Investor Contact:Chris Brinzey, Westwicke
Partners chris.brinzey@westwicke.com 339-970-2843
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2024 to May 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From May 2023 to May 2024